- The past year was a transformational time for Global Blood Therapeutics. The company was able to report growth for its flagship product, Oxbryta, in the face of COVID-19 headwinds.
- The company recently reported mixed earnings and revealed a hefty cash position.
- Global Blood Therapeutics revealed that Oxbryta received approval in the EU. The company now has several growth opportunities.
- The share price has chopped around for the last 7 months, as a result, I am looking to change up my strategy to a hybrid approach.
- I remain bullish on GBT's long-term outlook and will hold a core position in anticipation GBT becomes the leader in SCD and/or the company is acquired for a premium price.
For further details see:
Global Blood Therapeutics: Changing My Strategy After Recent Earnings